Core Viewpoint - The company is actively exploring the potential of its recombinant Staphylococcus aureus vaccine, which currently targets closed orthopedic surgeries, with plans to expand its applications to other clinical indications, particularly pressure ulcers, which affect over 4 million patients annually in China [2] Group 1: Vaccine Development and Market Potential - The recombinant Staphylococcus aureus vaccine has a broad market outlook as it can be extended to multiple departments related to hospital infections [2] - The company has initiated work on the second indication for the vaccine, targeting pressure ulcers, which represents a significant patient population in China [2] Group 2: Infection Statistics and Medical Needs - According to Zhi Shi Consulting, the number of MRSA infections in China is projected to reach 2.3 million cases in 2024, increasing to 2.6 million by 2035, while global MRSA cases are expected to reach 7.4 million by 2035 [2] - The high medical burden of Staphylococcus aureus infections and the growing issue of antibiotic resistance highlight the urgent need for effective vaccines, which remain unmet globally [2] Group 3: International Expansion - The company’s recombinant Staphylococcus aureus vaccine not only has a market foundation in China but also possesses potential for international expansion, with ongoing efforts to pursue related overseas collaborations [2]

证券日报网1月20日讯 ，欧林生物在接受调研者提问时表示，根据全国细菌耐药监测系统的公开数据以 及公司的流调数据等，金黄色葡萄球菌在近五年所有临床细菌分离株中排名前三位，居革兰氏阳性菌首 位；金葡菌中MRSA（耐药金葡菌）检出率在28%-30%之间波动。金葡菌主要感染科室包括：ICU（细 菌感染最集中，是普通病房的三倍以上）、皮肤科和烧伤科（软组织感染）、骨科手术部位感染、呼吸 内科（医院获得性肺炎）等。此外，特种人群（军人、消防战士）的贯穿伤/创伤伤口感染预防也是拓 展方向。 （文章来源：证券日报） ...

Core Viewpoint - The company is progressing normally with the Phase III clinical trial of the gold-staphylococcus vaccine, with no unblinding completed yet and no efficacy data results formed [2] Group 1: Clinical Trial Progress - The company expects to complete the initial and retesting of all serum samples by the end of Q1 this year [2] - Data cleaning is currently underway, with expectations to achieve a phase lock and conduct the first efficacy unblinding after obtaining serum test reports in the first half of this year [2] - The clinical trial progress and results may be influenced by various factors, and the final outcomes will be based on the company's public information [2]

Core Viewpoint - The company is focusing on the clinical application of the recombinant goldenseal vaccine, leveraging its existing promotion network established through the tetanus vaccine [1] Group 1: Clinical Application and Promotion Strategy - The primary use case for the recombinant goldenseal vaccine is clinical application [1] - The company has built a mature promotion network based on the tetanus vaccine promotion system [1] - The company plans to apply the successful experience from the tetanus vaccine to the recombinant goldenseal vaccine [1] Group 2: Market Education and Support - The company aims to support academic research and market education to standardize in-hospital diagnostic processes [1] - This initiative is intended to help reduce antibiotic-resistant bacterial infections [1] - The company is committed to ensuring efficient commercialization of the vaccine [1] Group 3: Sales and Promotion Activities - The sales team will initiate preliminary promotion activities based on the product application status of the recombinant goldenseal vaccine [1]

Core Viewpoint - The company has completed preclinical communication with the National Medical Products Administration (NMPA) regarding a second indication for pressure ulcers and is currently refining related research [1] Group 1 - The company is in the process of finalizing the clinical trial protocol, which will require further communication with the NMPA before submitting for clinical approval [1] - The company anticipates submitting the clinical application this year [1]

Core Viewpoint - Antimicrobial resistance (AMR) poses a significant threat to global health and economic stability, with the emergence of "superbugs" making infections harder to treat [1] Group 1: Impact of AMR - In 2019, an estimated 1.27 million deaths were directly attributed to bacterial AMR, with an additional 4.95 million deaths occurring indirectly [1] - The World Bank predicts that by 2050, AMR could lead to an increase in healthcare costs by $1 trillion [1] Group 2: Definition and Consequences - AMR refers to the mutations in bacteria, viruses, fungi, and parasites over time, resulting in the ineffectiveness of drugs and increased difficulty in treating infections [1] - The consequences of AMR extend beyond mortality and disability, leading to substantial economic losses [1]

Market Overview - The biopharmaceutical sector experienced a decline of 0.63% on January 20, with Olin Bio leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Tonghua Dongbao (600867) with a closing price of 8.81, up 2.20% on a trading volume of 319,000 shares and a turnover of 280 million yuan [1] - Wufan Bio (301393) closed at 55.20, up 1.81% with a trading volume of 22,900 shares and a turnover of 128 million yuan [1] - Kanghua Bio (300841) closed at 76.45, up 1.58% with a trading volume of 23,800 shares and a turnover of 183 million yuan [1] - Major decliners included: - Olin Bio (616889) closed at 25.98, down 3.88% with a trading volume of 87,000 shares and a turnover of 226 million yuan [2] - Junshi Bio (688180) closed at 35.29, down 3.42% with a trading volume of 119,400 shares and a turnover of 425 million yuan [2] - Ganli Pharma (603087) closed at 70.23, down 2.70% with a trading volume of 81,800 shares and a turnover of 577 million yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 335 million yuan from institutional investors, while retail investors experienced a net inflow of 128 million yuan [2] - The capital flow for specific stocks indicated: - Wanze Co. (000534) had a net inflow of 103 million yuan from institutional investors [3] - Watson Bio (300142) saw a net inflow of 40 million yuan from institutional investors [3] - Olin Bio (688319) had a net inflow of 17.96 million yuan from institutional investors [3]

Core Viewpoint - The company clarified that the share changes by directors and executives in January 2026 are not due to secondary market sell-offs, but rather a repurchase and cancellation operation in accordance with the "2023 Restricted Stock Incentive Plan" [1] Group 1 - The company responded to investor inquiries on its interactive platform regarding share changes [1] - The repurchase and cancellation of shares are part of the implementation of the "2023 Restricted Stock Incentive Plan" [1] - The details of the share repurchase and cancellation were disclosed in the announcement dated January 10, 2026, with the announcement number 2026-002 [1]

Group 1 - The core point of the article highlights the significant increase in the stock price of Olin Bio, which rose by 8.48% to reach 26.85 CNY per share, with a total market capitalization of 10.893 billion CNY [1] - Olin Bio, established on December 11, 2009, specializes in the research, production, and sales of human vaccines, with its main revenue sources being 90.99% from adsorbed tetanus vaccine, 4.49% from group A and C meningococcal polysaccharide conjugate vaccine, and 3.99% from type b Haemophilus influenzae conjugate vaccine [1] Group 2 - From the perspective of fund holdings, Olin Bio is a significant investment for Huafu Fund, with its Huafu Health and Entertainment Flexible Allocation Mixed A Fund holding 600,000 shares, representing 7.56% of the fund's net value, making it the fourth-largest holding [2] - The Huafu Health and Entertainment Flexible Allocation Mixed A Fund has achieved a year-to-date return of 12.99% and a one-year return of 42.45%, ranking 539 out of 9009 and 2957 out of 8164 respectively [2]

Group 1 - The stock of Olin Bio (688319) closed at 24.75 yuan on January 16, experiencing a decline of 15.21% with a trading volume of 5.15 billion yuan and a turnover rate of 4.67% [2] - The stock was listed on the daily trading list due to its closing price drop of 15% [2] - The top five trading departments accounted for a total transaction of 2.47 billion yuan, with a net buying amount of 39.22 million yuan [2] Group 2 - The main capital flow showed a net outflow of 1.32 billion yuan for the stock on the same day [3] - The top buying departments included the Shanghai-Hong Kong Stock Connect with a purchase amount of 51.95 million yuan, and a specialized institutional seat with a purchase of 22.26 million yuan [3] - The top selling department was also the Shanghai-Hong Kong Stock Connect, with a selling amount of 30.36 million yuan [3]